Woman Gets 5-Year Drug Import Ban, Ghosts Her Own Hearing
Published Date: 11/25/2025
Notice
Summary
Nicole Shelby Randall is officially banned for 5 years from importing any drugs into the U.S. because she was convicted of bringing in a bad drug that broke federal law. She didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on November 25, 2025. She can apply to end the ban anytime, but must follow special rules to keep her info private.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Five‑Year Import Ban for Nicole Randall
Nicole Shelby Randall is debarred for 5 years from importing or offering for import any drug into the United States, effective November 25, 2025. The debarment follows her January 22, 2025 felony conviction for introducing an adulterated drug into interstate commerce, and FDA states that importing drugs by, with the assistance of, or at the direction of Ms. Randall is a prohibited act.
Right to Apply and Public Filing Rules
Ms. Randall (or anyone seeking termination of debarment) may apply to end the debarment at any time under section 306(d)(1). Applications submitted electronically to https://www.regulations.gov will be posted publicly unchanged; to keep information confidential you must submit a written/paper application with two copies (one marked confidential and one redacted) to the Dockets Management Staff as described in the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16666, Determination That ANSAID (Flurbiprofen) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that ANSAID (flurbiprofen) tablets, 50 milligrams (mg) and 100 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for flurbiprofen tablets, 50 mg and 100 mg, if all other legal and regulatory requirements are met.
2026-16648, Determination That LASIX (Furosemide) Tablets, 20 Milligrams, 40 Milligrams, and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that LASIX (furosemide) tablets, 20 milligrams (mg), 40 mg, and 80 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
2026-16650, Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. PDUFA authorizes FDA to collect user fees to support the process for the review of human drug applications. The current legislative authority for PDUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. Following discussions with the regulated industry and periodic consultations with public stakeholders, the Federal Food, Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the recommendations for the reauthorized program in the Federal Register, hold a meeting at which the public may present its views on such recommendations, and provide for a period of 30 days for the public to provide written comments on such recommendations. FDA will then consider such public views and comments and revise such recommendations, as necessary.
Previous / Next Documents
Previous: 2025-21074, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on December 19, 2025, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info of applicants. Researchers waiting on funding decisions should note this date, but no new costs or changes to the process are announced.
Next: 2025-21076, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 6, 2026, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info. Scientists and researchers applying for grants should note this date, but no new costs or changes affect the public.